Poulet H, Brunet S, Boularand C, Guiot A L, Leroy V, Tartaglia J, Minke J, Audonnet J C, Desmettre P
Merial, Laboratoire de Lyon Gerland, 254 rue Marcel Merieux, 69007 Lyon, France.
Vet Rec. 2003 Aug 2;153(5):141-5. doi: 10.1136/vr.153.5.141.
Canarypox virus recombinant vaccines have a unique efficacy and safety profile for the vaccinated host because the canarypox virus is non-replicative in mammalian hosts. After the vaccination of a mammalian species, recombinant canarypox viruses express the inserted genes but cannot multiply in the host. They stimulate a strong immune response in the absence of any virus amplification in the host or any viral spread into the environment. A new canarypox-based recombinant vaccine is the canarypox-feline leukaemia virus (FeLV) vaccine (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes. This paper describes experiments which demonstrate that it is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge. Furthermore, the canarypox virus-FeLV vaccine was effective without an adjuvant.
金丝雀痘病毒重组疫苗对接种宿主具有独特的效力和安全性，因为金丝雀痘病毒在哺乳动物宿主中不具有复制能力。在对哺乳动物进行接种后，重组金丝雀痘病毒表达插入的基因，但无法在宿主体内增殖。它们在宿主体内不存在任何病毒扩增或任何病毒传播到环境中的情况下，刺激强烈的免疫反应。一种新的基于金丝雀痘病毒的重组疫苗是金丝雀痘 - 猫白血病病毒（FeLV）疫苗（EURIFEL FeLV；梅里亚公司），它表达FeLV env和gag保护性基因。本文描述的实验表明，它对任何经口鼻腔的FeLV攻击均有效。在初次接种一年后，该疫苗对经口鼻腔攻击显示出可靠的保护作用，并且对非常严重的“接触性”攻击也有效。此外，金丝雀痘病毒 - FeLV疫苗在没有佐剂的情况下也有效。
